Drugs / VG712
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07529405 | Jul 2026 → Dec 2030 expected | mycosis fungoides | Virogen Biotechnology Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VG712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07529405 ↗ |
| Action | Deplete | “VG712 is a recombinant anti-CD3 immunotoxin designed to selectively deplete CD3-positive T cells.” NCT07529405 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant anti-CD3 immunotoxin fusion protein” NCT07529405 ↗ |
| Route | Intravenous | “VG712 is administered intravenously to selectively deplete CD3-positive T cells.” NCT07529405 ↗ |